Table 2.
Ongoing phase 3 or 4, currently recruiting randomized clinical trials of IL-1 Inhibitors.
| Drug | Title | Design | ClinicalTrials.gov Identifier |
|---|---|---|---|
| Anakinra | Efficacy and Safety of ANAkinra During Adult “COVID-19” With Aggravating Respiratory Symptoms: a Multicenter Open-label Controlled Randomized Trial (ANACONDA) | Open label RCT | NCT04364009 |
| Anakinra | Clinical Trial of the Use of Anakinra in Cytokine Storm Syndrome Secondary to Covid-19. A Phase 2/3, Randomized, Open-label, Parallel Group, 2-arm, Multicenter Study Investigating the Efficacy and Safety of Intravenous Administrations of Anakinra, an Interleukin-1(IL-1) Receptor Antagonist, Added to Standard of Care, Versus Standard of Care, in Reducing Hyper-inflammation and Respiratory Distress in Patients With SARS- CoV-2 Infection (ANA-COVID-GEAS) | Open label RCT | NCT04443881 |
| Anakinra | A Phase 2/3, Randomized, Open-label, Parallel Group, 3-arm, Multicenter Study Investigating the Efficacy and Safety of Intravenous Administrations of Emapalumab, an Anti-interferon Gamma (Anti-IFNγ) Monoclonal Antibody, and Anakinra, an Interleukin-1(IL-1) Receptor Antagonist, Versus Standard of Care, in Reducing Hyper-inflammation and Respiratory Distress in Patients With SARS-CoV-2 Infection | Open label RCT | NCT04324021 |
| Anakinra | A Prospective, Randomized, Factorial Design, Interventional Study to Compare the Safety and Efficacy of Combinations of Blockade of Interleukin-6 Pathway and Interleukin-1 Pathway to Best Standard of Care in Improving Oxygenation and Short- and Long-term Outcome of COVID-19 Patients With Acute Hypoxic Respiratory Failure and Systemic Cytokine Release Syndrome | Open label RCT | NCT04330638 |
| Anakinra | Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (REMAP-CAP) | Open label RCT | NCT02735707 |
| Canakinumab | Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Canakinumab on Cytokine Release Syndrome in Patients With COVID-19-induced Pneumonia (CAN-COVID) | Double-blinded placebo-controlled RCT | NCT04362813 |
Abbreviations: IL-1, interleukin 1; RCT, randomized controlled trial; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.